Ann: US FDA Clearance for LiverSmart, page-35

With the rise of obesity not just in U.S. but all over the world the number of people with NASH ( Non alcoholic steatohepatitis ) will only grow, Muli billion dollars big pharmaceutical companies like Gilead and Novartis has some skin in the NASH game to develop drugs for NASH

NASH is the most severe form of fatty liver disease stemming predominantly from obesity, It has no approved drug and is currently treated with diet and exercise

if a patient get to lose 5% of their body weight, Their liver numbers are almost normal, If they lose 10% of their weight then fibrosis start to improve even without medication.

The above mentioned information is from Medical Journal from San Diego School of Medicine

Based on above, Looks like it's better to have liver scan for everyone and information about liver fat so it can be treated on time with good diet and exercise.

FDA approved Liver smart product has a huge upside potential and let's hope CPT codes can be generated ASAP

Hepion is another Biotech listed on Nasdaq working in the early stages of developing drug for NASH, market cap of $120 million AUD , 0 revenue and loss of 39 million Aud last financial year